The Shandra Eisenga Human Cell and Tissue Product Safety Act requires the Department of Health and Human Services to launch a national education campaign informing healthcare professionals and the public about the risks and benefits of human cell and tissue transplants, including information on organ and tissue donation procedures and donor screening tests. The bill establishes civil penalties of up to $20,000 per violation for companies that fail to comply with federal regulations governing these products, with additional penalties equal to the retail value of the products involved and a cap of $10 million per legal proceeding. The legislation also directs the FDA to publish educational materials and annual reports on the Tissue Reference Group, conduct stakeholder workshops, and submit recommendations to Congress by September 30, 2026, on modernizing the regulatory framework for these products. The bill affects tissue banks, healthcare facilities, and companies involved in cell and tissue product development and distribution, while benefiting patients seeking access to safe, regulated therapies.